Clinical Trial

Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis

Study acronym: BRAVO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-20.
Trial Details
NCT Number NCT07610837
Lead Sponsor AstraZeneca
Conditions Liver Fibrosis, Hepatic Cirrhosis
Enrollment 104 participants
Start Date 2026-05-07
Primary Completion 2027-07-07 (estimated)
Study Completion 2027-07-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-29